Bemarituzumab

Phase 3Monoclonal antibody

Amgen

Bemarituzumab is one of 169 small molecule programs targeting Esophageal Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

168

Competitors

Pipeline

Status by Indication[3][1]

Indication

Esophageal CancerActive, not recruiting

Esophageal AdenocarcinomaActive, not recruiting

Renal Cell CarcinomaActive, not recruiting

Gastric CancerActive, not recruiting

Solid TumorsTerminated

GrowthActive, not recruiting

Esophageal CancerPhase 1

Active, not recruiting

Esophageal AdenocarcinomaPhase 2

Active, not recruiting

Renal Cell CarcinomaPhase 2

Active, not recruiting

Gastric CancerPhase 3

Active, not recruiting

Solid TumorsPreclinical

Terminated

GrowthPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

714 competitors in Gastric Cancer

#DrugCompanyPhaseTrials

Camptosar

EEastern Cooperative Oncology Group

Phase 3

5 2

Bemarituzumab

Amgen

Phase 3

1 3

Gemzar

Johnson & Johnson

Preclinical

—4

Ftorafur

TThe First Affiliated Hospital with Nanjing Medical University

Preclinical

3 5

S1,

CChinese Academy of Medical Sciences

Preclinical

17 6

PD-1 Inhibitor

Johnson & Johnson

Preclinical

3 7

Induction Phase1

Genmab

Preclinical

1 8

Glutamine

Sanofi

Preclinical

1 9

Human Albumin

TTonghua Anrate Biopharmaceutical Co., Ltd.

Preclinical

1 10

Capecitabine, Oxaliplatin

PPeking Union Medical College Hospital

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 1/2Active, not recruiting

Gastroesophageal Junction Cancer

NCT05322577

Q1 2027

Phase 3Active, not recruiting

Gastroesophageal Junction Cancer

NCT05111626

Q2 2029

Phase 2Not yet recruiting

Renal Cell Carcinoma

NCT07470840

Q3 2029

Phase 1Not yet recruiting

Esophageal Cancer

NCT06978062

Clinical

Trials by Indication[1]

Gastroesophageal Junction Cancer2 trials

A Study Evaluating Bemarituzumab in Combination With Other Anti-cancer Therapies in Subjects With Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer.

Active, not recruiting· Amgen logo

Amgen·Phase 1/2·NCT05322577·72 enrolled

Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.

Active, not recruiting· Amgen logo

Amgen·Phase 3·NCT05111626·515 enrolled

Esophageal Cancer2 trials

A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 in Gastric/Gastroesophageal Cancer

Completed·FFive Prime Therapeutics, Inc.·Phase 1·NCT03343301·12 enrolled

Peri-operative Treatment of Resectable Gastroesophageal Cancer Using Bemarituzumab (BEMA) Plus Perioperative Treatment

Not yet recruiting·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 1·NCT06978062·27 enrolled

Bevacizumab1 trial

AssociatiNG Bevacizumab bEmarituzumab for GynecoLogIcal CAncer

Not yet recruiting·CCentre Leon Berard·Phase 1/2·NCT07146919·87 enrolled

Gastric Cancer1 trial

Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression

Active, not recruiting· Amgen logo

Amgen·Phase 3·NCT05052801·547 enrolled

Esophageal Adenocarcinoma1 trial

PANGEA-IMBBP: Personalized Antibodies for Gastro-Esophageal Adenocarcinoma - A 1st Pilot Metastatic Trial of Biologics Beyond Progression

Completed·UUniversity of Chicago·Phase 2·NCT02213289·80 enrolled

4 more indications

Monotherapy1 trial

A Study of Bemarituzumab Monotherapy and Combination With Other Anti-cancer Therapy in SqNSCLC With FGFR2b Overexpression (FORTITUDE-201)

Terminated· Amgen logo

Amgen·Phase 1·NCT05267470·74 enrolled

Renal Cell Carcinoma1 trial

SBRT Plus Anlotinib and Bimepolizumab in Locally Advanced or Metastatic Renal Cell Carcinoma

Not yet recruiting·FFujian Cancer Hospital·Phase 2·NCT07470840·27 enrolled

Gastric/Gastroesophageal Junction Cancer1 trial

A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (mFOLFOX6) in Gastric/Gastroesophageal Junction Cancer

Completed·FFive Prime Therapeutics, Inc.·Phase 2·NCT03694522·155 enrolled

Solid Tumors1 trial

A Phase 1b/2, Multicenter, Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors With FGFR2b Overexpression (FORTITUDE-301)

Terminated· Amgen logo

Amgen·Preclinical·NCT05325866·260 enrolled

Sources

References

[1]
ClinicalTrials.gov — 11 trial records for Bemarituzumab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Bemarituzumab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Bemarituzumab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Amgen company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 3[1]
Company: Amgen

Bemarituzumab

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Q1 2027

Q2 2029

Q3 2029

Trials by Indication[1]

Gastroesophageal Junction Cancer2 trials

Esophageal Cancer2 trials

Bevacizumab1 trial

Gastric Cancer1 trial

Esophageal Adenocarcinoma1 trial

Monotherapy1 trial

Renal Cell Carcinoma1 trial

Gastric/Gastroesophageal Junction Cancer1 trial

Solid Tumors1 trial

References

Drug Info

Quick Facts

Related News